Real-World Treatment Patterns and Survival Among Patients with Stage I–III, Non-Squamous, Non-Small Cell Lung Cancer Receiving Surgery as Primary Treatment

This is the authors' abstract. We don't add key points for this paper.

Approximately half of patients with non-small cell lung cancer (NSCLC) present with early-stage disease at diagnosis. Real-world outcomes data are limited for this population but are of interest given recent and impending results from trials evaluating epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and immunotherapies in neoadjuvant, adjuvant, and perioperative settings.